As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging
The DOI matches its Crossref record.
Abstract
This Medical News article discusses Wegovy, Ozempic, and other GLP-1 receptor agonists used for weight management and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00355-1 · Cited by 1,151
“Various pharmacotherapies for obesity have been launched in the past; 93 however, uptake was slow 94 due to the risk of serious side-effects 95,96 and contraindications for conditions such as cardiovascular diseases, which are common among individuals with obesity.”
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 344
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
“Monitoring and caution are advised when prescribing these drugs, particularly for individuals with a history of suicidality [44].”
BackgroundGLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Metadata
- Authors
- Ruder, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-12-12
- Volume
- 330
- Issue
- 22
- Pages
- 2140
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4388695236
- Cited by
- 53
- References
- 0
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging. https://app.cochat.ai/papers/10.1001/jama.2023.16620
- The paper
- Ruder, K. (2023). As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging. JAMA. https://doi.org/10.1001/jama.2023.16620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.